6-Benzoyl-3-Methylbenzoic Acid

6-Benzoyl-3-Methylbenzoic Acid

SCHEMBL5309754

Cc1ccc(C(=O)c2ccccc2)c(C(=O)O)c1

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.68
POLB P06746 2/20 0.67
CDC25B P30305 2/20 0.59
CDC25A P30304 1/20 0.59
HSD17B10 Q99714 1/20 0.59
KDM4E B2RXH2 1/20 0.58
NPSR1 Q6W5P4 1/20 0.55
CSNK2A1 P68400 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LTC4S Q16873 1/20 0.52
MEN1 O00255 1/20 0.51
GFER P55789 1/20 0.51
KMT2A Q03164 1/20 0.51
FNTA P49354 1/20 0.51
FNTB P49356 1/20 0.51
TP53 P04637 1/20 0.51
ATM Q13315 1/20 0.50
NPC1 O15118 1/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
6-Benzoyl-3-Methylbenzoic Acid SCHEMBL5484402 0.98 AKR1C3 (0.66) AKR1C3POLBCDC25BCDC25AHSD17B10
SCHEMBL9217336 0.93 AKR1C3 (0.68) AKR1C3POLBCDC25BCDC25AHSD17B10
SCHEMBL28384878 0.92 AKR1C3 (0.61) AKR1C3POLBKDM4ENPSR1MEN1
SCHEMBL4638917 0.86 AKR1C3 (0.54) AKR1C3POLBKDM4ENPSR1TP53
SCHEMBL5484397 0.86 AKR1C3 (0.54) AKR1C3POLBKDM4ENPSR1MEN1
SCHEMBL1821601 0.84 NR4A1 (0.62) AKR1C3POLBCDC25BCDC25AHSD17B10
SCHEMBL16363711 0.84 POLB (0.60) AKR1C3POLBCDC25BCDC25AHSD17B10
SCHEMBL9327289 0.84 AKR1C3 (0.51) AKR1C3POLBKDM4ENPSR1MEN1
SCHEMBL11587451 0.83 AKR1C3 (0.70) AKR1C3POLBCDC25BCDC25AHSD17B10
SCHEMBL29356028 0.83 NPSR1 (0.60) AKR1C3POLBNPSR1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4292142-A MIXTURE OF PHTHALIC ANHYDRIDE AND MALEIC ANHYDRIDE INTERNATIONAL SYNTHETIC RUBBER CO., LTD. (GB) 1981-09-29 US claimed
US-20230278989-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM ASTEX THERAPEUTICS LIMITED (GB) 2023-09-07 US disclosed
US-10544132-B2 Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity ASTEX THERAPEUTICS LIMITED (GB) 2020-01-28 US disclosed
US-20190016708-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2019-01-17 US disclosed
WO-2007044184-A1 WATER SOLUBLE PHOTOINITIATOR ALBEMARLE CORPORATION (US) 2007-04-19 WO disclosed
US-20070066837-A1 Podophyllotoxin derivatives as antitumor agents RANBAXY LABORATORIES LIMITED (IN) 2007-03-22 US disclosed
EP-1599485-A2 PODOPHYLLOTOXIN DERIVATIVES AS ANTITUMOR AGENTS RANBAXY LABORATORIES, LTD. (IN) 2005-11-30 EP disclosed
WO-2004073375-A2 PODOPHYLLOTOXIN DERIVATIVES AS ANTITUMOR AGENTS RANBAXY LABORATORIES LIMITED (IN) 2004-09-02 WO disclosed
EP-0569457-B1 USE OF THIAZOLO-[2,3-A]ISOINDOLE DERIVATIVES AS ANTIVIRAL MEDICAMENTS AND NOVEL THIAZOLO- [2,3-A]ISOINDOLE DERIVATIVES BOEHRINGER MANNHEIM GMBH (DE) 1995-06-14 EP disclosed
WO-1992013863-A1 USE OF THIAZOLO-[2,3-A]ISOINDOLE DERIVATIVES AS ANTIVIRAL MEDICAMENTS AND NOVEL THIAZOLO-[2,3-A]ISOINDOLE DERIVATIVES BOEHRINGER MANNHEIM GMBH (DE) 1992-08-20 WO disclosed
EP-0210415-B1 PROCESS FOR PRODUCING CRYSTALLINE ORGANIC MATERIALS BASF Aktiengesellschaft (DE) 1991-10-30 EP disclosed
US-4769200-A EXTRUSION PULVERIZED MOLTEN MATERIAL THROUGH TWIN-SCREW EXTRUDER IN WHICH SCREWS ROTATE IN SAME DIRECTION; EJECTION TO LOW PRESSURE ZONE, COOLING, AND COMMINUTION; SHELF LIFE BASF AKTIENGESELLSCHAFT (DE) 1988-09-06 US disclosed
EP-0210415-A2 Process for producing crystalline organic materials BASF Aktiengesellschaft (DE) 1987-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544132-B2 Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity TP53, MDM2, TP53BP1 AKR1C3 2044/4885POLB 1106/4885CDC25B 65/4885
US-20070066837-A1 Podophyllotoxin derivatives as antitumor agents DIMT1, CYP51A1, MAGT1 AKR1C3 1820/4885POLB 3725/4885CDC25B 88/4885
US-20230278989-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM MDM2, TP53, TP53BP1 AKR1C3 1327/4885POLB 874/4885CDC25B 70/4885
US-20190016708-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY TP53, MDM2, TP53BP1 AKR1C3 2044/4885POLB 1106/4885CDC25B 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.